Paula Ortiz, MD
Internal Medicine · West Haven, CTNPI 1619358124
Payments from drug & device makers
Across 127 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$354
- Boehringer Ingelheim$285
- Otsuka America Pharmaceutical, Inc.$269
- Lilly USA, LLC$265
- Neurocrine Biosciences, Inc.$257
- Novo Nordisk$214
- plus $1K from 14 others
What the payments were for
- Food & beverage$2,882100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $354 |
| Boehringer Ingelheim | 14 | $285 |
| Otsuka America Pharmaceutical, Inc. | 3 | $269 |
| Lilly USA, LLC | 15 | $265 |
| Neurocrine Biosciences, Inc. | 3 | $257 |
| Novo Nordisk | 9 | $214 |
| Amgen | 4 | $187 |
| AstraZeneca | 12 | $184 |
| Pfizer | 11 | $177 |
| Johnson & Johnson | 10 | $133 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $124 |
| Astellas Pharma US Inc | 6 | $123 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $62 |
| Novartis | 2 | $37 |
| Ironwood Pharmaceuticals, Inc | 1 | $29 |
| Endo Pharmaceuticals Inc. | 1 | $21 |
| Exact Sciences | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,889 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 425 | $121,761 |
| NuplazidPimavanserin Tartrate | 15 | $38,469 |
| FarxigaDapagliflozin Propanediol | 50 | $21,910 |
| XareltoRivaroxaban | 61 | $20,054 |
| OzempicSemaglutide | 19 | $19,850 |
| MounjaroTirzepatide | 15 | $13,825 |
| JardianceEmpagliflozin | 34 | $11,541 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $11,456 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $10,018 |
| Sevelamer Hcl | 17 | $9,933 |
| Spiriva HandihalerTiotropium Bromide | 12 | $8,997 |
| RexultiBrexpiprazole | 19 | $8,638 |
| EntrestoSacubitril/Valsartan | 25 | $8,549 |
| TradjentaLinagliptin | 27 | $7,111 |
| JanuviaSitagliptin Phosphate | 24 | $6,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $177 | $121,761425 claims |
| AstraZenecaFarxiga, Lokelma, Symbicort | $184 | $35,08178 claims |
| Johnson & JohnsonXarelto | $133 | $20,05461 claims |
| Novo NordiskOzempic | $214 | $19,85019 claims |
| Boehringer IngelheimJardiance, Tradjenta | $285 | $18,65261 claims |
| Lilly USA, LLCMounjaro | $265 | $13,82515 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $269 | $8,63819 claims |
| NovartisEntresto | $37 | $8,54925 claims |
| Astellas Pharma US IncMyrbetriq | $123 | $4,85021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in West Haven
- Daniel FedermanWest Haven$24K
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
- Gary BlickNorwalk$717K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.